Vanguard Capital Management Establishes 5.09% Stake in Travere Therapeutics Inc (TVTX)

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, reporting a new 5.09% stake in Travere Therapeutics Inc (TVTX). As of the event date of March 31, 2026, the investment adviser beneficially owns 4,699,424 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 4,699,424 shares, while maintaining sole voting power over 653,612 shares. This position was acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reported holdings include securities managed by various Vanguard affiliates, such as Vanguard Global Advisers, LLC and Vanguard Asset Management Limited. Previously, the filer reported no ownership, marking this as a significant new institutional position in the biopharmaceutical company. The total value of the holdings is estimated at approximately $207.34 million based on the filing data.